Cost-effectiveness analysis of two-way texting for post-operative follow-up in Zimbabwe's voluntary medical male circumcision program.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
12
2019
accepted:
16
09
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
16
12
2020
Statut:
epublish
Résumé
Although adverse events (AEs) following voluntary medical male circumcision (VMMC) are rare, their prompt ascertainment and management is a marker of quality care. The use of two-way text messaging (2wT) for client follow-up after VMMC reduces the need for clinic visits (standard of care (SoC)) without compromising safety. We compared the cost-effectiveness of 2wT to SoC for post-VMMC follow-up in two, high-volume, public VMMC sites in Zimbabwe. We developed a decision-analytic (decision tree) model of post-VMMC client follow-up at two high-volume sites. We parameterized the model using data from both a randomized controlled study of 2wT vs. SoC and from the routine VMMC program. The perspective of analysis was the Zimbabwe government (payer). The time horizon covered the time from VMMC to wound healing. Costs included text messaging; both in-person and outreach follow-up; and AE management. Costs were estimated in 2018 U.S. dollars. The outcome of analysis was AE yield relative to the globally accepted safety standard of a 2% AE rate. We estimated the incremental cost per percentage increase in AE ascertainment and the incremental cost per additional AE identified. We conducted univariate and probabilistic sensitivity analyses. 2wT increased the costs due to text messaging by $4.42 but reduced clinic visit costs by $2.92 and outreach costs by $3.61 -a net savings of $2.10. 2wT also increased AE ascertainment by 50% (92% AE yield in 2wT compared to 42% AE yield in SoC). Therefore, 2wT dominated SoC in the incremental analysis: 2wT was less costly and more effective. Results were generally robust to univariate and probabilistic sensitivity analysis. 2wT is cost-effective for post-VMMC follow-up in Zimbabwe. Countries in which VMMC is a high-priority HIV prevention intervention should consider this mHealth intervention to reduce overall cost per VMMC, increasing the likelihood of current and future VMMC program sustainability.
Identifiants
pubmed: 32997710
doi: 10.1371/journal.pone.0239915
pii: PONE-D-19-34591
pmc: PMC7526887
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0239915Subventions
Organisme : FIC NIH HHS
ID : R21 TW010583
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e50-7
pubmed: 23846561
Lancet HIV. 2016 May;3(5):e212-20
pubmed: 27126488
J Int AIDS Soc. 2017 Feb 20;19(1):21394
pubmed: 28362066
Health Syst Reform. 2018;4(4):284-299
pubmed: 30376401
J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):16-23
pubmed: 31809358
PLoS One. 2012;7(2):e30735
pubmed: 22363480
Trials. 2019 Jul 23;20(1):451
pubmed: 31337414
Glob Health Action. 2018;11(1):1414997
pubmed: 29322867
Lancet. 2007 Feb 24;369(9562):643-56
pubmed: 17321310
J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 4:S264-72
pubmed: 27404007
Clin Infect Dis. 2018 Apr 3;66(suppl_3):S166-S172
pubmed: 29617778
JMIR Res Protoc. 2016 Jul 26;5(3):e155
pubmed: 27460771
Public Health. 2019 May;170:57-60
pubmed: 30933882
MMWR Morb Mortal Wkly Rep. 2013 Nov 29;62(47):953-7
pubmed: 24280914
AIDS. 2011 Mar 27;25(6):825-34
pubmed: 21252632
PLoS Med. 2011 Nov;8(11):e1001129
pubmed: 22140364
PLoS One. 2010 Mar 10;5(3):e9628
pubmed: 20224784
Lancet. 2007 Feb 24;369(9562):657-66
pubmed: 17321311
PLoS Med. 2005 Nov;2(11):e298
pubmed: 16231970
PLoS One. 2012;7(9):e43832
pubmed: 22957034
PLoS One. 2014 May 06;9(5):e80577
pubmed: 24801209
PLoS Med. 2011 Nov;8(11):e1001132
pubmed: 22140367
Hum Resour Health. 2008 Jan 10;6:1
pubmed: 18186916
Lung Cancer. 2018 Oct;124:189-198
pubmed: 30268459